This umbrella review summarizes the available evidence on personalized antiplatelet strategies and risk-stratification tools to guide treatment decisions in cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Personalized antiplatelet strategies lack conclusive evidence for routine use; leaves open the need for prospective validation trials.
inhibitor monotherapy for long-term secondary prevention, the implementation of parenteral antiplatelet agents in high-ischemic risk clinical settings, and combination of antiplatelet agents with low-dose factor Xa inhibitors (dual pathway inhibition) in patients suffering from polyvascular disease. This review summarizes the currently available evidence and provides an overview of the principal risk-stratification tools and antiplatelet strategies to inform treatment decisions in patients with cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Oliva et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: